Home » Posts tagged 'cardiovascular events'

Tag Archives: cardiovascular events

Bad science: “In Studies, Invokana Improves Diabetes Patients’ Kidney Health”



 Author’s Conclusion

The author of this article was not listed but the article concluded that “the results from the integrated analysis showed canagliflozin significantly reduced the combined risk of CV death, myocardial infarction (MI), and nonfatal stroke versus placebo in patients with T2DM at risk for, or with a history of, CV disease. Additional analysis revealed canagliflozin treatment was associated with a reduced risk of hospitalization for heart failure and demonstrated potential renal protective effects. Canagliflozin demonstrated consistent improvement of renal outcomes across multiple composite endpoints that were independently confirmed by an Endpoints Adjudication Committee.”

Student’s Conclusion (Nyesha Fulton)

The article that I found was published on a site called Managed Care by an unknown author. This article mainly discusses the use of the oral diabetic medication, Canagliflozin, to treat diabetes type 2 and its potential renal protective benefits by reducing the risk of kidney disease progression, reducing urinary albumin excretion and stabilizing estimated glomerular filtration rate. The article concluded that Canagliflozin reduced the rates of renal endpoints (end-stage kidney disease, renal death, etc.) by 47% (95% confidence interval [CI], 33%–84%). The article also goes on to state urinary albumin excretion was 18% lower in all participants treated with Canagliflozin compared with placebo (95% CI, 16%–20%). Overall the article suggested that the study demonstrated consistent improvement of renal outcomes across multiple composite endpoints. The article doesn’t seem to be a reliable source. The article didn’t have an author listed nor a direct link to the primary literature, but instead to another article where they plagiarized half of that article. Also, the results from the article and the results from the primary literature didn’t quite match up exactly, which made the results questionable. Therefore, based on these findings, or lack thereof, I wouldn’t recommend this article.



Good science: “HF Patients Steady as Rock with Short-Term High-Dose Caffeine”


Author’s Conclusion

The Author of the article express that long-term safety of moderate and high dose consumption of caffeine including in popular energy drinks and in patients at high risk for arryhytmias, remain unknown. For the time being, it seems reasonable to reassure our patients that modest caffeine consumption appears to be safe, including for most patients with heart failure.

Student’s Conclusion (Nebiat Mekonnen)

The article, and the study that the article highlights, discusses and assesses the effect of high doses of caffeine in patients with HF. As an intuitive notion that caffeine intake should be limited in patients with heart failure because of the intrinsic factors. Although the study sought to shed light on how taking high doses of caffeine does not appear to increase coronary artery events. The median plasma caffeine concentration was 9480 microgram over liters in the caffeine group. Based on the data presented It was found that coffee intake is fine unless patients have bothersome symptoms and arrhythmias.